RKT
+0.0 · +0.00%
GBX · LSE

Reckitt Benckiser Group PLC(RKT) Stock Analysis | Consumer Defensive

GBX --+0.00%
Reward51Moderate
Risk19Low
75%Data
Strong 21% profit margin · 4.2% dividend yield · Revenue down 8% YoY
Dividend King
Market Cap:32.46Bn
ⓘ
Reward Rating
51
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
19
Low
Risk Assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RKT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Reckitt Benckiser Group PLC?

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally.

AI Brief Pro

The brief on Reckitt Benckiser Group PLC

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Reckitt Benckiser Group PLC?

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. The company is listed on the LSE in UK, operating in the Consumer Defensive sector, with a market capitalisation of 32.46B, and a P/E ratio of 11.5x.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (51)

Similar stocks to compare

A short list of Household & Personal Products names that are close enough in size to make side-by-side comparison useful.

All Consumer Defensive stocks →
Company Information
IndustryHousehold & Personal Products
P/E Ratio11.544
Beta0.252
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.

Openbook research

Articles mentioning RKT

3